CSE: IZO OTC: IZOZF FRA: 1R3
Vancouver BC, November 18, 2019
Izotropic Corporation (“Izotropic” or the “Company”) engaged in the development and commercialization of its dedicated breast CT cancer detection platform, is pleased to announce the appointment of Ralph Proceviat to the board of directors of the Company.
“We are pleased to welcome Ralph as a valued addition to the Board” said Robert Thast, CEO and Chairman of Izotropic. “Ralph’s many successful years as a CPA, CA, C-level executive and board member of private and publicly traded companies, will provide strength in several financial, corporate governance and operational areas of the business, as we prepare for the rollout of our ground-breaking CT Imaging system”.
Mr. Proceviat has more than 35 years in business, finance, markets and operations spanning several industries operating in Canada, Europe and the United States including high tech, software development, manufacturing, telecommunications, real estate and most recently, life sciences. Currently, as Co-founder of the RAMP Executive Consulting Group Inc. (“RAMP”) a professional advisory services firm based in Vancouver, B.C., Ralph provides strategic C-level management and business advisory services to RAMP’s clients.
Mr. Proceviat commented: “I’m very excited for the opportunity to join my fellow board members of Izotropic at this critical stage in the development and roll out of the Company’s cost-effective breast CT imaging and diagnostic system that will offer greater accuracy, speed and comfort to women of all ages”.
Mr. Proceviat is a member of the Chartered Professional Accountants of BC and holds a Bachelor of Commerce Degree in Management Information Systems from the University of British Columbia.
The appointment of Mr. Proceviat to the Company’s board of directors follows the resignation of Mr. D. Barry Lee from the board. The board and management of Izotropic thank Mr. Lee for his efforts and contributions and wish him well in his future endeavors.
About Izotropic Corp.
The company is engaged in the development and commercialization of 3-D breast CT imaging technology for early diagnosis of breast cancer, that improves patient comfort, provides true high-resolution images and delivers high diagnostic accuracy. The company has also established Izotropic Imaging Corp, a wholly owned Nevada based subsidiary that will manage operations in the U.S.A.